DOTA-TATE

<p>DOTA-TATE (DOTATATE, DOTA-octreotate, oxodotreotide, DOTA-(Tyr3)-octreotate, and DOTA-0-Tyr3-Octreotate) is an eight <a href="/facts/Amino_acid/WDxYwBny">amino acid</a> long <a href="/facts/Peptide/C4ltc7UG">peptide</a>, with a <a href="/facts/Covalent_bond/EzMLf3Pz">covalently</a> bonded <a href="/facts/DOTA_(chelator)/3AVXsU92">DOTA</a> <a href="/facts/Chelation/4G79sXBB">bifunctional chelator</a>.
</p><p>DOTA-TATE can be reacted with the <a href="/facts/Radionuclide/5WpCfbdq">radionuclides</a> <a href="/facts/Gallium-68/Wk0C9DbY">gallium-68</a> (T1/2 = 68 min), <a href="/facts/Lutetium-177/yUu2IeCp">lutetium-177</a> (T1/2 = 6.65 d) and <a href="/facts/Copper-64/1KBmNStU">copper-64</a> (T1/2 = 12.7 h) to form <a href="/facts/Radiopharmaceutical/x3g6zbB6">radiopharmaceuticals</a> for <a href="/facts/Positron_emission_tomography/5SmcW6qz">positron emission tomography</a> (PET) imaging or <a href="/facts/Unsealed_source_radiotherapy/UCzGRPxo">radionuclide therapy</a>. 177Lu DOTA-TATE therapy is a form of <a href="/facts/Peptide_receptor_radionuclide_therapy/ElNkqQf5">peptide receptor radionuclide therapy</a> (PRRT) which targets <a href="/facts/Somatostatin_receptor/HaEBsQC9">somatostatin receptors</a> (SSR). In that form of application it is a form of <a href="/facts/Targeted_drug_delivery/cRjKKv6l">targeted drug delivery</a>.
</p>

DOTA-TATE open-in-new

DOTA-TATE